Ependymoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Video
• Funding
• Clinical Trials
• Forums

A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Conditions:   Medulloblastoma;   Glioblastoma Multiforme;   Anaplastic Astrocytoma;   High-grade Astrocytoma NOS;   Anaplastic Oligodendroglioma;   Anaplastic Ependymoma;   Ependymoma;   Diffuse Intrinsic Pontine Glioma Interventions:   Biological: SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years;   Biological: SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 27, 2021 Category: Research Source Type: clinical trials